This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dal Maso, L. Articles by Franceschi, S. Search for Related Content PubMed PubMed Citation Articles by Dal Maso, L. Articles by Franceschi, S. Related Collections Epidemiology and Prevention Epidemiology and Prevention: Genetics and Biomarkers

Hepatitis C Virus and Risk of Lymphoma and Other Lymphoid Neoplasms: A Meta-analysis of Epidemiologic Studies

¹ Epidemiology and Biostatistics Unit, Aviano Cancer Center, Aviano, Italy and ² International Agency for Research on Cancer, Lyon, France

Requests for reprints: Luigino Dal Maso, Epidemiology and Biostatistics Unit, Centro di Riferimento Oncologico, IRCCS, Via Pedemontana occidentale 12, 33081 Aviano (PN), Italy. Phone: 39-0434-659354; Fax: 39-0434-659222. E-mail: epidemiology{at}cro.it

The present meta-analysis was conducted to evaluate the strength and the consistency of the association between hepatitis C virus (HCV) infection and non–Hodgkin lymphoma (NHL) and other lymphoid neoplasms. Only studies with 100 cases which were also adjusted for sex and age were included. Fifteen case-control studies and three prospective studies contributed to present analysis, nine of which had not been included in previous meta-analyses. We calculated the pooled relative risks (RR) with corresponding 95% confidence intervals (95% CI), as a weighted average of the estimated RRs by random-effect models. The pooled RR of all NHL among HCV-positive individuals was 2.5 (95% CI, 2.1-3.0), but substantial heterogeneity was found between studies and by study design. Pooled RRs were 2.5 (95% CI, 2.1-3.1) in case-control studies and 2.0 (95% CI, 1.8-2.2) in cohort ones. The strongest source of heterogeneity seemed to be the prevalence of HCV among NHL-free study subjects (RR for NHL among HCV-positive individuals 3.0 and 1.9, respectively, for 5% and <5% HCV prevalence). RRs were consistently increased for all major B-NHL subtypes, T-NHL, and primary sites of NHL presentation. Thus, previous suggestions that the RRs for HCV differed by NHL subtype were not confirmed in our meta-analysis. Associations weaker than with NHL were found between HCV infection and Hodgkin's lymphoma (RR, 1.5; 95% CI, 1.0-2.1) and multiple myeloma (RR, 1.6; 95% CI, 0.7-3.6), but they were based on much fewer studies than NHL. The etiologic fraction of NHL attributable to HCV varies greatly by country, and may be upward of 10% in areas where HCV prevalence is high. (Cancer Epidemiol Biomarkers Prev 2006;15(11):2078–85)

This article has been cited by other articles:

				L. M. Brown, G. Gridley, D. Check, and O. Landgren Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders Blood, April 1, 2008; 111(7): 3388 - 3394. [Abstract] [Full Text] [PDF]

				L. M. Morton, O. Landgren, N. Chatterjee, D. Castenson, R. Parsons, R. N. Hoover, and E. A. Engels Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients Blood, December 15, 2007; 110(13): 4599 - 4605. [Abstract] [Full Text] [PDF]

				D S Viswanatha and A Dogan Hepatitis C virus and lymphoma J. Clin. Pathol., December 1, 2007; 60(12): 1378 - 1383. [Abstract] [Full Text] [PDF]

				T. P. Giordano, L. Henderson, O. Landgren, E. Y. Chiao, J. R. Kramer, H. El-Serag, and E. A. Engels Risk of Non-Hodgkin Lymphoma and Lymphoproliferative Precursor Diseases in US Veterans With Hepatitis C Virus JAMA, May 9, 2007; 297(18): 2010 - 2017. [Abstract] [Full Text] [PDF]